Oncology Drugs

A new alliance aims to develop first-in-class drugs for Alzheimer's and Parkinson's by targeting chronic brain inflammation, a key driver of disease.

A new drug targeting the root cause of sebum production shows promise in clinical trials, offering hope for millions of moderate to severe acne sufferers.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

The Italian pharma giant appoints a global health policy heavyweight, signaling a strategic pivot towards tackling complex global challenges and a new era.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Following a landmark FDA approval and strong earnings, Axsome must convince investors its momentum can translate into long-term profitability and leadership.

The biotech's blockbuster Nasdaq debut provides crucial capital for its promising pipeline, offering new hope for patients with severe bleeding conditions.

A strategic investment from FreeMind Investments and Daewoong Pharma validates General Proximity's novel platform for next-gen induced proximity medicines.

The clinical-stage biotech adds seasoned veterans from Eli Lilly and Iovance to accelerate its promising DNA Damage Response pipeline toward commercialization.

Valitor's VLTR-559 shows superior durability in preclinical data, potentially slashing wet AMD treatment from monthly injections to just two per year.

An ultra-rare disease affects thousands, but few are diagnosed. Now, a new alliance of industry and advocates is racing to solve the diagnostic puzzle.

Contineum Therapeutics reports encouraging early data for its non-opioid drug PIPE-791, offering a potential new weapon in the fight against chronic pain.

With double-digit growth and key US acquisitions, ESTEVE is rapidly expanding. But it's the firm's B Corp status that may redefine success in pharma.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

A novel, FDA-cleared wound therapy is rolling out to military and veteran hospitals, aiming to rewrite the rules of healing for the most complex injuries.